Podcasts about Pharma

Today on DANGER CLOSE: THE FOURTH OPTION, I'm joined by Gerald Posner.Gerald is an investigative journalist, attorney, Pulitzer Prize finalist, and the author of thirteen books including CASE CLOSED, WHY AMERICA SLEPT, GOD'S BANKERS, and PHARMA.In this episode, we get into the pharmaceutical industry, the opioid crisis, the Sackler family, the JFK assassination and the conspiracy industry that grew in its aftermath, and the duty to follow the evidence wherever it leads.We also discuss how secrecy, power, money, and institutional failure shape public trust, and what it takes to stay focused on the facts.This is a companion podcast to my new thriller, THE FOURTH OPTION, talking to those on the front lines, analyzing modern warfare, and taking listeners deeper into the themes that inspired the novel.This podcast series is presented by HUXWRX Safety Co., Staccato 2011, and Bravo Company.Learn more about Gerald Posner: https://www.posner.com/Follow Gerald on Instagram: https://www.instagram.com/posnergram/Order: THE FOURTH OPTIONBooks by Gerald Posner:PHARMA: Greed, Lies, and the Poisoning of AmericaCASE CLOSEDGOD'S BANKERS: A History of Money and Power at the VaticanWHY AMERICA SLEPT: The Failure to Prevent 9/11

The evidence that someone planned Nancy Guthrie's kidnapping months in advance was everywhere online. Google Trends screenshots appearing to show searches for her Tucson address in June and Savannah Guthrie's salary in December. It looked damning. It circulated on every platform. People cited it as proof that whoever took Nancy had been researching her family's wealth for months. Then NewsNation reporter Brian Entin did something nobody else had bothered to do — he called Google. Google's answer: the search data as presented was not accurate. The searches as described didn't happen. The most-shared evidence of premeditation in the Nancy Guthrie case was not real. And it wasn't alone. A separate YouTube video fabricated Nancy's entire professional identity — placing her in Columbus, Ohio, calling her a pharmaceutical compliance officer, and building a 25-minute conspiracy about healthcare fraud retaliation. Nancy has never been a healthcare executive. She's never lived in Ohio. One search would have debunked it. Tony Brueski walks through both fabrications in detail and asks the question the internet never asked: what happens to a real investigation when manufactured evidence floods the system?Links:Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodDisclaimer:This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.Hashtags:#NancyGuthrie #NancyGuthrieUpdate #TrueCrimeToday #FindingNancy #TrueCrime #GuthrieCase #NancyGuthrieDebunked #TrueCrimePodcast #SavannahGuthrie #NancyGuthrieFake

In 2020, Emily Mendenhall drove from Washington, DC to Okoboji, Iowa, a town of 800 that swells to 200,000 every summer, and walked into a pandemic that looked nothing like the one dominating national headlines. Inside gas stations and bars, masks marked you as an outsider. In one stop, a man told her family they would not be served if they kept theirs on. Her 6 year old daughter cried, confused. Mendenhall, a medical anthropologist at Georgetown University, did what she always does. She started asking questions. Over months, she interviewed neighbors, former classmates, and local officials, including her own brother in law who helped lead the local COVID response. The result became Unmasked, a case study in how community identity, economics, and politics shaped public health decisions in real time. That work led directly into her latest book, Invisible Illness: A History, from Hysteria to Long COVID, where she tracks a much older problem. Patients with chronic illness, especially women, often fail to meet medicine's demand for proof. Without a clear diagnosis, they lose access to care, insurance coverage, and legitimacy. Mendenhall argues that long COVID did not create this failure. It exposed it.This conversation centers on how healthcare systems reward certainty and punish complexity. Long COVID clinics send patients to 17 specialists without resolution. Insurance structures require diagnoses that many conditions cannot provide. Medical training still struggles to integrate trauma, mental health, and chronic disease into a coherent model of care.Mendenhall brings lived experience into the conversation. After COVID, she dealt with months of fatigue and escalating anxiety that altered her baseline health. She does not claim the label of long COVID, but she understands how quickly the system becomes harder to navigate once symptoms stop fitting clean categories. The stakes are not theoretical. In the United States, access to healthcare, disability benefits, and treatment still depends on whether a condition can be measured, coded, and reimbursed. For millions living with invisible illness, the burden of proof becomes the illness itself.RELATED LINKSEmily MendenhallInvisible Illness: A History, from Hysteria to Long COVIDScience PoliticsGeorgetown UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A YouTube video with hundreds of thousands of views claimed Nancy Guthrie was a pharmaceutical compliance officer from Columbus, Ohio, connected to a 32 billion dollar healthcare fraud conspiracy. The video stated it as fact. Professional narration. Graphics. The production quality of legitimate reporting. The problem: Nancy Guthrie was born in Fort Wright, Kentucky. She's lived in Tucson, Arizona for more than fifty years. She's a retired grandmother. She was never a compliance officer. She never lived in Ohio. The entire professional identity was fabricated. The theory that grew from it — that Nancy was a whistleblower silenced by corporate interests — was built on a foundation that doesn't exist. And a separate fabrication made it worse: manipulated Google Trends screenshots claiming someone in Arizona searched for Nancy's address months before the kidnapping. Google itself confirmed through Brian Entin at NewsNation that the data was not accurate. Two manufactured pieces of evidence. Two pillars of the case's online mythology. Both completely made up. Tony Brueski examines how the internet built an evidence factory around a real missing person — and why the content creators behind it are still collecting views.Links:Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodDisclaimer:This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.Hashtags:#NancyGuthrie #NancyGuthrieUpdate #HiddenKillers #FindingNancy #TrueCrime #GuthrieCase #NancyGuthrieFraud #TrueCrimePodcast #SavannahGuthrie #TucsonCrime

Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== Pharma is one of the largest employers of physicians outside hospitals and insurance companies, and most available roles don't require research experience, an advanced degree, or even a completed residency. In this solo masterclass, John breaks down how pharma companies are structured, which divisions actually hire physicians, and what it takes to land a first role. He walks through the major departments: clinical development, medical affairs, and safety/pharmacovigilance. And explains the role contract research organizations (CROs) play in hiring physicians faster than pharma companies often do directly. Six real examples from this podcast's guests illustrate how physicians without residency training, board certification, or research backgrounds broke into roles ranging from safety scientist to medical science liaison to primary investigator. You'll find links mentioned in the episode at nonclinicalphysicians.com/nonclinical-pharma-careers/.

USTR is writing prescriptions for pressure with the launch of a new Section 301 investigation into Germany's drug pricing system. Listen for more on Two Minutes in Trade. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve, with significant scientific advancements, regulatory updates, and strategic business moves shaping the landscape. Let's delve into these developments, starting with some key insights from oncology. In the realm of oncology, minimal residual disease (MRD) is becoming increasingly pivotal. Tumor-informed MRD is being leveraged to design more intelligent trials and interpret early responses, aiding in navigating developmental risks more effectively. This approach was a focal point of discussions at the American Society of Clinical Oncology's annual meeting, where experts emphasized the need to translate precision oncology discoveries into patient care, aiming to surmount existing challenges. The focus on MRD in oncology could lead to earlier detection of treatment responses and personalized therapeutic approaches. Verastem Oncology recently revisited its strategy concerning its combination treatment of avutometinib plus defactinib for metastatic pancreatic cancer. While clinical trials produced moderate results, the company is now redirecting focus toward other promising candidates in its pipeline. Similarly, Novocure faced setbacks as its tumor-treating electric fields device did not achieve its primary endpoint in a Phase 3 glioblastoma trial. These outcomes highlight the persistent challenges in tackling aggressive brain cancers. On the regulatory front, Spero Therapeutics achieved a significant milestone with FDA approval for Utebzi to treat complicated urinary tract infections. This approval marks a turnaround from a previous rejection four years ago, facilitated through a partnership with GSK. Meanwhile, in Europe, Cinnagen secured approval for Zandoriah, a biosimilar of teriparatide, to treat osteoporosis in adults—a testament to their investment in infrastructure and manufacturing capabilities. The industry also sees growing interest in cell therapy automation, with companies like Cellares and Ori Biotech leading the charge. These advancements reflect an industry-wide push towards more efficient manufacturing processes for cell therapies. In metabolic health, Novo Nordisk's oral GLP-1 drug Wegovy has gained significant traction due to its brand familiarity among healthcare providers, crucial in its competition with Eli Lilly's Foundayo. Market trends reveal competitive dynamics within obesity treatments as Novo Nordisk's oral Wegovy outpaces Eli Lilly's offerings due to strong brand recognition. Biogen's acquisition of Raythera for $1 billion underscores its strategic intent to enhance its portfolio with promising preclinical immunology assets. Such acquisitions highlight broader industry strategies focusing on expanding pipelines through targeted investments. This move aligns with Biogen's focus on autoimmune diseases and enhances its preclinical portfolio. In business development news, LabGenius Therapeutics partnered with LG Chem to utilize AI and machine learning for designing multispecific antibodies targeting tumors. This collaboration highlights the growing importance of artificial intelligence in accelerating drug discovery processes within oncology. Clinical trials continue to yield promising results. F2G and Shionogi's antifungal small molecule olorofim demonstrated efficacy comparable to Ambisome in treating invasive aspergillosis—an advancement crucial for infectious diseases with limited treatment options. D&D Pharmatech's Zabopegdutide showed an impressive improvement rate in fibrosis during Phase 2 trials for metabolic dysfunction-associated steatohepatitis, emphasizing the potential of protein-based therapies in treating metabolic liver disorders. Corporate launches reflect strategic maneuvers aimed at advancing therapeutic developments. Innoviva introduced Nortiva Bio to focus on long-acting oral medicines using acquired platform technology from Lyndra Therapeutics—aiming to revolutionize women's health through sustained-release formulations. The financial landscape also shows active movement, exemplified by Kardigan's $400 million IPO aimed at progressing cardiovascular drugs into advanced trials. Alvotech's public offering signals a commitment to biosimilar medicines—a sector poised for growth due to rising demand for cost-effective biologic therapies. Overall, these developments reflect a robust innovation pipeline within the pharmaceutical and biotech industries as they strategically address complex diseases through novel therapies and technologies. As scientific progress accelerates alongside strategic corporate actions, these changes promise enhanced patient care outcomes through groundbreaking treatments that cater to unmet medical needs worldwide.Support the show

What if 90–95% of cancers weren't written in your genes—but in your environment, lifestyle, and daily choices? My guest today Dr B challenges some of the biggest assumptions in modern medicine, drawing on decades of experience examining cancer cells under the microscope. From the hidden drivers of chronic disease to the controversial role of hormone replacement therapy and the critical importance of gut health, this episode explores what happens when we stop asking what disease a person has and start asking why they developed it in the first place.With an unprecedented five board certifications, Dr. Monisha Bhanote brings a comprehensive, systems-based approach to health that few practitioners can match.As the founder of WELLKULÅ and CEO of Travela Wellness, Dr. Bhanote has created comprehensive platforms that make transformative health accessible to individuals and organizations worldwide. Dr B's work bridges the gap between ancient wisdom traditions and modern molecular science, creating personalized, actionable protocols that deliver measurable results.Her clinical and research focus centers on the microbiome-brain-longevity axis—investigating how gut health, inflammation management, and cellular optimization.Contact:Website - https://www.drbhanote.comJoin us as we explore:Breaking genetic dogma once and for all around disease pathology - from cancer to diabetes. Balancing the pros and cons of any approach whether conventional, Pharma or Ayurvedic.A long ranging conversation on hormonal replacement therapy. Tumor vs healthy cell biology.The crisis of gut health, the gut “clock” you didn't know you had and why many answers lie with the millennia old wisdom of Ayurvedic and Chinese medicine.The stress travel puts on your microbiome due to stress, dehydration, hypoxia, humidity, radiation and poor food choices.MentionsStudy - The Negative Influence of Air Travel on Health and Performance in the National Basketball Association: A Narrative Review, https://pmc.ncbi.nlm.nih.gov/articles/PMC6162549/Support the showFollow Steve's socials: Instagram | LinkedIn | YouTube | Facebook | Twitter | TikTokSupport the show on Patreon:As much as we love doing it, there are costs involved and any contribution will allow us to keep going and keep finding the best guests in the world to share their health expertise with you. I'd be grateful and feel so blessed by your support: https://www.patreon.com/MadeToThriveShowSend me a WhatsApp to +27 64 871 0308. Disclaimer: Please see the link for our disclaimer policy for all of our content: https://madetothrive.co.za/terms-and-conditions-and-privacy-policy/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

Only roughly 50% of new GLP-1 prescriptions were getting approved for coverage in 2023. From a plan sponsor's seat, that looks like pharmacy trend spiking 9%, 12%, even 20% year over year. From a pharma manufacturer's seat, it's half their prescriptions not getting filled. Same market, opposite problems — and that's exactly the lens this episode flips on. In this episode, Stacey Richter speaks with Ophelia Johnson, who built new business channels for a pharmaceutical manufacturer that created the GLP-1 boom and has since launched a consulting practice at e-fi.works, about how cash pay models work from the inside — coupon platforms, telehealth channels, white label pharmacy models, and employer carve-outs — and where the new fees are hiding. WHAT YOU'LL LEARN ✅ How the Inflation Reduction Act, PBM legal scrutiny, drug shortages, and the compounding bypass converged with ~50% GLP-1 prior auth denial rates in 2023 to push pharma into building cash pay channels that cut the PBM out entirely ✅ How the savings coupon model works: manufacturer buys the patient down to a flat transparent cash price via platforms like GoodRx, pays a fixed per-script fee instead of a PBM rebate, and the coupon platform makes the pharmacy whole — transparent math, no black box ✅ How the telehealth channel and white label pharmacy models extend the distribution chain beyond retail — and why shipping costs, credit card fees, dispensing fees, and new supply chain partners create gross-to-net and revenue leakage risk for manufacturers not built for it ✅ Why "direct to employer" is a misnomer: PBM contracts prohibit pharma from selling directly to self-insured employers, so third-party transparent administrators have emerged — but plan sponsors need to run the math first, given ERISA complications and PBM contract leverage ✅ How PBMs are now charging fees for hub-like patient support services to manage the exact prior auth complexity they created — a Whack-a-Mole shift of profitability that everyone needs to map before signing anything ✅ Ophelia's three-part practical advice: map the full patient journey and all ecosystem player incentives before building any new model (pharma); treat affordability as a clinical risk factor (clinicians); demand auditable medication abandonment data rather than settling for rebate yield metrics (plan sponsors) WHY THIS MATTERS If collaboration is the next innovation, everyone has to understand the incentives of every player in the ecosystem — not just their own. The same 50% of unfilled GLP-1 prescriptions that looks like runaway pharmacy trend from a plan sponsor's seat looks, from a manufacturer's seat, like half their market going dark — and both sides are making moves that affect each other. Understanding those moves, where fees are being layered on, and when fair profit tips into what Stacey calls profiteering is what this episode maps. TUNE IN NEXT WEEK Next week is the 401-level companion to this one — Stacey goes solo on the PBM and GPO contracting mechanics behind why cash pay became a thing, and why cheaper or better drugs can inexplicably end up off formulary or buried under prior auth. === LINKS ===

I coach women through interviews all the time. So when I had to sit in one myself, for the first time in over 12 years, I learned something I want you to hear. Even though interviewing is something I teach regularly, doing it myself, under pressure, with the outcome out of my hands, was a different experience. So I recorded a raw voice memo the moment I walked out, before I knew if I got in. In this episode I play you that unedited memo, then break down exactly what I did so you can do it too.In this episode, you'll learn:Why I prepared with bullets instead of a script, and what I put on that list before I had my panel interviewThe kinds of questions I asked that took the interrogation feeling out of the room and got me real answersWhat I watched for across everyone I talked to, and what that one pattern told me about the cultureThe question almost nobody asks at the end of an interview, and why one interviewer lit up when I asked itWhy the confidence I felt walking out had nothing to do with whether I got the spotI received the outcome two months later. I'll tell you how it went, and why the answer matters less than you think.REGISTER: The next Strategy Hour for Women in Pharma and Biotech is July 9th. Secure your spot here.Get the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here.Work with Me: Learn more and apply to work with me here.Love the podcast?  Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Get your CBD today at Emerald MED with 30% off up to 2 items: https://www.emeraldmedcbd.com/awk?ref=andweknow  ————— Protect your investments with And We Know http://andweknow.com/gold Or call 720-605-3900, Tell them “LT” sent you. ————————— ➜ Our AWK Website: https://www.andweknow.com/ ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ------- *DONATIONS SITE: https://bit.ly/2Lgdrh5 *Mail your gift to: And We Know 30650 Rancho California Rd STE D406-123 (or D406-126) Temecula, CA 92591 ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ➜ Audio Bible https://www.biblegateway.com/audio/mclean/kjv/1John.3.16 Connect with us in the following ways: + DISCORD Fellows: https://discord.gg/kMt8R2FC4z

One of the hardest parts of auditing is not knowing what to look for.It is deciding where to start. Do you trace a deviation? Walk the process? Focus on one department? Audit CAPA across the organization? Or pull on a thread that does not quite make sense?In this video, Subhi walks through six audit strategies from the ASQ Certified Quality Auditor Body of Knowledge and explains how they apply in real-world pharma, biotech, and combination product audits.The six strategies covered are:1. Tracing2. Process Approach3. Process-Based Management4. Department Method5. Element Method6. Discovery MethodThese approaches are useful whether you are auditing a supplier, a manufacturing site, a testing laboratory, or a quality system that spans drug, device, and combination product responsibilities.Need support with combination product quality, auditing, supplier quality, or quality system strategy?Schedule a Let's Combinate intro call:https://calendly.com/letscombinate/let-s-combinate-intro-sessionLearn more about Let's Combinate:https://letscombinate.comPreparing for the CQA exam?Check out the CQA Master Class here:https://cqeacademy.teachable.com/p/the-cqa-master-class-courseChapters:00:00 Six Audit Strategies Overview01:12 Tracing Method Explained02:59 Process Approach Workflow04:27 Process-Based Management05:46 Department Method Deep Dive06:27 Element Method Across the QMS07:12 Discovery Method: Pull the Thread08:55 Summary: Pros and Cons11:31 Final Tips and Next StepsSubhi Saadeh is the Founder and Principal of Let's Combinate, where he helps teams develop and control drug-device combination products by aligning quality systems, development, and regulatory expectations across drug and device domains. He is a consultant, auditor, trainer, and speaker with experience across pharma, biotech, medical devices, and combination products.#Pharma #Biotech #Quality #Auditing #QualityAudits #CQA #GMP #CombinationProducts #QualitySystems #ISO13485

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

It's not easy to talk about cancer. After all, cancer is a broad, yet deeply personal disease state. There are common cancers, rare cancers, cancers with preventative treatment options and challenging cancers that are usually terminal.  Nearly every medical marketing agency has to message around this incredibly complicated, sensitive health topic – for some it's even their sole focus.  Across MM+M's digital, print and audio arms, we tend to cover a lot of cancer awareness campaigns and major scientific developments in the oncology space. The attention paid to cancer now extends well past the awareness months dedicated to the various subsets of the disease.  Our pharma editor Lecia Bushak just returned from ASCO, where thousands converged to discuss the future of cancer and how we should communicate about it. Cancer is the subject of countless decades of research by some of the leading academic institutions around the world as well as the subject of acute anxiety experienced by patients and their caregivers.  With that in mind, Avalere Health CEO Amar Urhekar returns to the show alongside chief creative officer TJ Cimfel to discuss the Within Reach project. Launched shortly before ASCO, Within Reach isn't a campaign from the Agency 100 honoree. As the two Avalere Health leaders explain, Within Reach is a multimedia anthology that supports patients and caregivers with real-life stories and clinical insights to better understand and navigate all aspects of cancer care.  And in lieu of the Trends segment, our reporter Bella Czajkowski brings us a conversation with ViiV Healthcare about its latest PrEP campaign during Pride Month.    Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Founder of Brighthive Innovation Group's Leandra Wells discusses tech enablement, transforming organization on lean budgets, and prioritizing healthcare in Canada. Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe

New Guest Expert! On this week's Aftermath, Rebecca revisits the rise and fall of Crystal Pepsi with Professor Ernest Baskin. Chair of the Food, Pharma and Healthcare Department at Saint Joseph's University, Ernest shares some fascinating insights about the world of consumer market research, advertising and distribution tactics. Afterward, Patreon subscribers can join the post-interview discussion and revisit the board with Fact Checker Faryn Einhorn and Producer Clayton Early. Not part of the Patreon family yet? Click below and join us!Join our Patreon!Tell us who you think is to blame at http://thealarmistpodcast.comEmail us at thealarmistpodcast@gmail.comFollow us on Instagram @thealarmistpodcastFollow us on TikTok @thealarmistpodcastSupport this show http://supporter.acast.com/alarmist. Hosted on Acast. See acast.com/privacy for more information.

You can't scroll through your feed for five seconds without seeing someone talking about Ozempic, Wegovy, or the newest GLP-1 drug.But here's what nobody is telling you: your body was already designed to make its own version of this appetite-suppressing hormone. However, most of us have stopped feeding the good bacteria responsible for producing it.In this episode, I'm breaking down the gut-centric theory of hunger, a fascinating concept that completely changed the way I think about appetite, cravings, and weight management. Plus, I'll share what happened when I personally experimented with a specific category of food for my upcoming book and experienced something I can only describe as... injecting GLP-1. Without the injection.On this episode, you'll learn: The science behind what GLP-1 actually is (1:40)The real reason you feel like you can't stop eating (and what you can do to stop it) (4:33)All about the jaw-dropping Chinese study where volunteers minimized their hunger (9:03)Exactly which foods crank up your body's natural GLP-1 production (11:29)The one food category I added to my own diet that had me leaving half my meal on the plate (13:43)For the full episode transcript and show notes: https://drgundry.com/how-to-boost-glp1-naturally Thank you to our sponsors! Check them out: Take your water to the next level with the AquaTru water purifier, go to aquatruwater.com and enter code “GUNDRY20” at checkout for 20% off.Get $20 off your first box plus a free year of protein, like sirloin or ribeye at ButcherBox.com/GUNDRY.Visit Juvent.com/GUNDRY and use code GUNDRY at checkout to get an extra $300 off your Juvent Micro-Impact Platform.Get a quote today at Progressive.com.Shop my new air filter, Homekind Total Air! Use code CLEANAIR for 10% off. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The future of market access belongs to organizations that plan years in advance. In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity, explains why pharmaceutical companies must prepare now for major market access changes coming in Europe and beyond. He highlights that Joint Clinical Assessments for rare disease assets, beginning in 2028, will require earlier planning, stronger governance, and more integrated evidence-generation strategies. Steve also discusses the complexity created by varying country-specific care pathways, limited comparators, and the growing importance of real-world evidence in rare disease development. Across policy shifts like JCA, IRA, MFN, and new European pharmaceutical legislation, the central message is clear: organizations that anticipate earlier will be better positioned to succeed. Tune in to hear how the future of rare disease market access is being reshaped, and why companies that prepare earlier will have a major strategic advantage! Resources: Connect with and follow Steve Mather on LinkedIn. Follow Lumanity on LinkedIn and explore their website! Learn more about this series we're doing with Lumanity here:  https://lumanity.com/commercialization-podcasts/

Gerald Posner is an American investigative journalist and author of 13 New York Times bestsellers including Case Closed: Lee Harvey Oswald and the Assassination of JFK, God's Bankers, and Pharma. He was previously a litigation associate on Wall Street before doing years of pro bono representation for surviving twins of Nazi experiments, which led to his first book, Mengele: The Complete Story. This episode is brought to you by "Weekly Wealthy Wisdom" my free weekly E-newsletter. Sign up now at www.bryankuderna.com.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a series of pivotal advancements and challenges shaping the industry landscape—ranging from scientific breakthroughs to regulatory maneuvers, all underscoring the sector's dynamic evolution. Novartis has made headlines with its investigational drug, Delpacibart Braxlosiran, which successfully met primary endpoints in a Phase 1/2 trial for treating Facioscapulohumeral Muscular Dystrophy (FSHD). This RNA therapy utilizes an antibody-oligonucleotide conjugate to target the DUX4 gene, a significant cause of FSHD. The promising results not only mark a potential therapeutic breakthrough for this debilitating neuromuscular disease but also highlight Novartis' commitment to innovative treatments in rare diseases. In parallel, Enliven Therapeutics has reported positive outcomes from a Phase 1 trial of ELVN-001 for patients with Chronic Myeloid Leukemia (CML), who are heavily pretreated. This small molecule tyrosine kinase inhibitor shows improved efficacy, offering hope for those who have exhausted existing treatment options. As ELVN-001 progresses into later-stage trials, it may significantly enhance therapeutic options and outcomes for CML patients. Regulatory activities remain at the forefront, exemplified by Amgen's engagement with the Duke Clinical Research Institute to defend Tavneos amid an FDA push for market withdrawal. This illustrates the intricate complexity of regulatory processes and the importance of evidence-based advocacy in preserving access to critical therapies. In another regulatory development, Guardant Health's Guardant360 CDx has received FDA approval as a companion diagnostic for Boehringer Ingelheim's Hernexeos targeting HER2-mutant non-small cell lung cancer. The approval emphasizes the growing significance of liquid biopsy technologies in personalized oncology care, offering precise and less invasive diagnostic solutions. In business development news, strategic collaborations are gaining momentum. Simcere Pharmaceutical has partnered with Stanford Medicine to develop first-in-class therapies for Idiopathic Pulmonary Fibrosis. Meanwhile, Ildong Pharmaceutical and Welt are joining forces to create AI-driven digital therapeutics. These alliances reflect an increasing trend towards integrating cutting-edge technology and cross-disciplinary expertise to accelerate drug discovery and development. Funding dynamics within the sector are evolving, as seen with Neion Bio's successful Series A fundraising of $23 million aimed at enhancing its biologics manufacturing platform. Similarly, Human Continuum secured $5.13 million to advance its exosome-based regenerative medicine platform. These investments underscore a strong focus on innovative platform technologies promising to transform therapeutic modalities and manufacturing processes. Not all news is positive, however; Jazz Pharmaceuticals and PharmaMar faced setbacks as their Phase 3 trial for Zepzelca (Lurbinectedin) failed to meet its overall survival endpoint in metastatic small cell lung cancer. This highlights the inherent challenges in oncology drug development and underscores the need for continuous innovation. Regulatory hurdles persist as well, evidenced by Camurus receiving a second complete response letter from the FDA regarding Oclaiz (Octreotide) due to manufacturing concerns. The industry is also navigating cybersecurity challenges, as seen with Novo Nordisk's recent data breach incident. This breach underscores vulnerabilities within biopharma companies concerning intellectual property and patient data protection. It serves as a stark reminder of the necessity for robust cybersecurity measures to safeguard sensitive information critical to clinical trials and corporate integrity. Meanwhile, strategic planning remains essential as Astellas confronts a looming $6 billion patent cliff with Xtandi, its prostate cancer drug. The company's five-year strategy focuses on cost savings while sustaining innovation and competitiveness amidst impending revenue declines. The biotechnology sector continues to thrive amidst these challenges, evidenced by record levels of initial public offerings (IPOs). Despite broader economic uncertainties, investor confidence remains robust, highlighting biotech's potential for groundbreaking advancements and lucrative returns. Finally, artificial intelligence is making significant strides across health agencies, with a reported 148% increase at the FDA by 2025 alone. This surge in AI integration highlights its transformative potential in regulatory processes and healthcare delivery—offering opportunities to enhance efficiency and decision-making within the sector. In summary, today's developments encapsulate the vibrant pharmaceutical and biotech industries characterized by scientific innovation, regulatory intricacies, strategic collaborations, and financial maneuvers. These advancements offer new hope for patients while navigating complex landscapes that demand continuous innovation and compliance—a balance that defines success in this ever-evolving sector.Support the show

Pharma ads have a language of their own. See omnystudio.com/listener for privacy information.

Episode Notes **More than $200 billion in pharma revenue is at risk from patent expirations through 2030, and TA teams are caught in the middle. Reducing legacy field forces, staffing specialty launches, and opening reshored plants often happen at the same time, on systems that weren't built for any of it. In this episode of Talent Experience Live, we break down three of the highest-pressure hiring scenarios in pharma right now and show exactly which AI agents are helping TA teams run them in parallel — without burning out their recruiters or cutting corners on compliance.**

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy.  This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one.  The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of remarkable updates that highlight the dynamic evolution of drug development, regulatory landscapes, and industry strategies. Takeda has made waves with its TYK2 inhibitor, Zasocitinib, which recently outperformed Bristol Myers Squibb's Sotyktu in a pivotal Phase 3 trial for plaque psoriasis. This trial is particularly noteworthy as it involves TYK2 inhibitors, a class of drugs targeting tyrosine kinase 2 to modulate immune responses. The success of Zasocitinib not only strengthens Takeda's competitive position but also underscores the potential of these inhibitors in treating autoimmune conditions like psoriasis. As we look forward to its market launch next year, this development represents a significant stride in the realm of targeted therapies aimed at complex diseases. Shifting gears to regulatory advancements, Johnson & Johnson's Darzalex (daratumumab) has received endorsement from NICE for its quadruplet therapy in newly diagnosed transplant-ineligible multiple myeloma cases. This approval is based on favorable Phase 3 trial results and highlights the therapeutic potential of targeting CD38 on myeloma cells. This marks a crucial step in offering potent treatment options to patients who cannot undergo transplants, emphasizing the growing importance of combination therapies in oncology. In another significant development, Johnson & Johnson is expanding its rare disease portfolio with promising Phase 2/3 trial data for Imaavy. Poised to become the first approved treatment for warm autoimmune hemolytic anemia, this advancement highlights the industry's pivot towards addressing rare diseases with limited treatment options. In India, AstraZeneca has secured CDSCO approval for Enhertu (trastuzumab deruxtecan) combined with pertuzumab as a first-line treatment for HER2-positive unresectable or metastatic breast cancer. This approval signifies a milestone in HER2-targeted therapies, spotlighting the pivotal role of antibody-drug conjugates that deliver cytotoxic agents directly to cancer cells, enhancing efficacy while minimizing systemic exposure. Moving on to business developments, Servier's partnership with N-Lorem Foundation to develop antisense oligonucleotide therapies for rare neurological disorders reflects the industry's increasing focus on precision medicine. This collaboration underscores the burgeoning interest in nucleic acid-based therapies aimed at addressing genetic disorders lacking effective treatments. On the financial front, Kardigan's planned $320 million IPO signals robust confidence in advancing cardiovascular pipeline assets. This move highlights Kardigan's commitment to tackling substantial unmet needs in cardiovascular diseases—an area still rife with challenges despite existing therapies. From a regulatory perspective, China's update of its Good Clinical Practice guidelines aims to streamline clinical trial processes, fostering biotech innovation. This change is expected to enhance drug development efficiency and attract global biotech investments to China's rapidly growing pharmaceutical market. Meanwhile, Pfizer CEO Albert Bourla has raised concerns about Germany's healthcare reform plans, warning that they might deter future investments. His comments underscore the delicate balance between cost containment policies and maintaining an environment conducive to pharmaceutical innovation. Additionally, Novo Nordisk's CEO Mike Doustdar expressed optimism about the company's strategic focus on market positioning through innovation and efficiency improvements. This aligns with broader industry trends where large pharma companies strive to maintain leadership roles amid fierce competition. Eli Lilly's sponsorship of short films premiered at Tribeca Festival illustrates an industry-wide trend toward patient-centric approaches and authentic portrayals of people with diseases onscreen. Such efforts aim to enhance communication strategies that resonate with diverse audiences. Furthermore, transformative technologies like cell and gene therapies are gradually moving towards mainstream clinical adoption. This transition necessitates zero-tolerance logistics to ensure these complex therapies reach patients safely and effectively—a paradigm shift offering potential cures but also posing logistical challenges. Finally, industry events such as ASCO continue to spotlight cutting-edge research developments in oncology. Such conferences are pivotal in advancing treatment paradigms and fostering collaborations that drive innovation across the sector. These updates reflect a period marked by groundbreaking scientific advances and strategic initiatives poised to reshape patient care and global healthcare solutions. As companies navigate these complexities while addressing regulatory and economic challenges, maintaining a focus on innovation will be key in charting future growth trajectories within the pharmaceutical and biotech sectors.Support the show

Bei Google hat der Berliner Gründer einst eines der berühmtesten KI-Forschungspapiere der Welt verfasst. Jetzt entwickelt er mit seinem Start-up „biologische Software“.

At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

No dilly-dallying around if you want reduced sutures on your drugs. Applications to lower 100% tariffs are due tomorrow. Listen for more on Two Minutes in Trade. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The pharmaceutical and biotech industries are undergoing significant transformations, driven by scientific advancements, regulatory changes, and strategic investments. These developments are shaping the landscape of drug development and patient care in profound ways. In recent news, Pfizer's CEO, Albert Bourla, is reconsidering investments in Germany due to proposed healthcare reforms. These reforms have sparked concerns about their potential impact on the pharmaceutical industry. This situation highlights the intricate balance between regulatory frameworks and corporate strategies, illustrating how policy changes can influence investment decisions and operational strategies within the pharma sector. The tension between regulatory environments and corporate interests is a recurring theme that continues to shape strategic directions within the industry. Meanwhile, heightened scrutiny over biotechnology operations is evident with Wuxi AppTec's inclusion on the Pentagon's blacklist under the Biosecure Act. This move reflects growing concerns about biosecurity and the necessity for stringent oversight in handling sensitive biotechnological advancements. Such actions underscore a global focus on safeguarding national security while fostering scientific innovation. Teva Pharmaceuticals is navigating restructuring efforts by laying off 250 employees at its Active Pharmaceutical Ingredients unit as it seeks a new owner. This restructuring underscores the challenges companies face in maintaining operational efficiency amid ownership transitions. These challenges are emblematic of broader industry dynamics where companies strive to adapt to changing market conditions while ensuring stability and growth. On the scientific front, Novo Nordisk's cagrisema and Eli Lilly's retatrutide are emerging as next-generation incretin therapies. Although early comparisons have been made, Novo Nordisk's chief scientific officer suggests it is premature to declare a definitive leader. This competition reflects the dynamic nature of drug development as companies strive to innovate and improve treatment options continuously. Additionally, Sonothera's successful $125 million Series B funding round for its bubble-based genetic delivery system highlights the biotech industry's momentum fueled by mergers and acquisitions (M&A) and partnerships. Such technologies promise to advance genetic therapies by enhancing delivery mechanisms, potentially transforming treatment paradigms for various genetic disorders. AbbVie's Skyrizi narrowly surpassing Johnson & Johnson's Tremfya in May drug ad spending underscores the competitive nature of pharmaceutical marketing. Despite a general slump in advertising expenditures among leading drugs, strategic marketing remains crucial for maintaining brand presence and market share. Increased M&A activity and partnerships are further bolstering the industry's growth trajectory. The resurgence of Initial Public Offerings (IPOs) and venture capital funding is fostering innovation and expansion within the sector, providing fuel for continued advancement in biotech. On the regulatory front, Johnson & Johnson's Darzalex received a new endorsement from NICE after a prior reversal. Such regulatory updates emphasize the evolving nature of drug approvals and market access strategies essential for pharmaceutical companies' success. Novartis' second deal with Orionis Biosciences worth up to $1.4 billion exemplifies strategic investments aimed at expanding research capabilities and addressing unmet medical needs through molecular glue technologies targeting challenging therapeutic areas. Conversely, Sanofi's decision to halt a Phase 3 autoimmune trial due to insufficient efficacy highlights the inherent risks in drug development pipelines. These setbacks emphasize the importance of robust clinical trial designs and adaptability in R&D strategies. Emerging insights into GLP-1 drugs like Novo Nordisk's semaglutide reveal potential antidepressant effects linked to gut microbiota modulation. These findings open new avenues for exploring psychiatric applications of metabolic drugs, although conflicting data necessitates further investigation. Overall, these developments illustrate a complex interplay of scientific innovation, regulatory dynamics, and strategic corporate actions driving the future of pharmaceuticals and biotechnology. The sector continues to navigate challenges while capitalizing on opportunities to enhance patient care through advanced therapeutic solutions. The industry's trajectory promises transformative impacts on patient care through novel therapies designed not only to treat symptoms but also address root causes via innovative science-driven solutions. As these advancements unfold, they herald a new era of targeted, effective treatments that hold promise for improving patient outcomes across diverse medical landscapes.Support the show

AI is moving incredibly fast across the life sciences sector, but many organizations still struggle to build systems that deliver real operational value. In this episode, tech leader Rose LaRocca-Fisch explains why strong data governance and business alignment must come before chasing software trends. Please visit our website to get more information: https://swangroup.net/ Rose shares her practical leadership experience guiding pharmaceutical companies, CDMOs, and global biotech organizations through massive growth. The discussion breaks down why high-profile tech implementations collapse and outlines the exact steps needed to prepare your infrastructure for enterprise-grade tools.Key themes covered in this conversation:Why does advanced software amplify existing operational flaws instead of fixing themThe OASIS framework for sustainable and scalable IT transformationHow data readiness directly impacts clinical trial success and manufacturing yieldsReal-world applications using platforms like Databricks to speed up patient enrollmentThe shift toward AI-assisted work and managing data integrity risksLinks from this episode:Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup Get to know more about Rose LaRocca-Fisch: https://www.linkedin.com/in/rose-larocca-fisch 

Pharma commercial teams are generating more data than ever, but field intelligence is still arriving too late to change rep behavior before the engagement window closes. In this episode, Damion Nero, Global Head of Statistics at Daiichi Sankyo, joins Emerj editor Yolandi de Weerdt to examine why fragmented data pipelines, not a shortage of data, are the structural root of the gap between commercial insight and field execution. The conversation covers what separates teams that successfully adopt AI from those stuck in the pilot phase, and why starting with routine, high-certainty use cases consistently produces more commercial lift than chasing ambitious automation. This episode is sponsored by ODAIA. Learn how leading organizations approach AI investment more like a venture portfolio, and why interdisciplinary collaboration is critical to defining the right data for AI success. Download our free PDF report, "Beginning with AI," at emerj.com/aik1

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Executive Dose Podcast, host Stephen Beckman leads a timely discussion on how pharmaceutical manufacturers approach portfolio ideation, portfolio development, and strategic growth in today's increasingly complex healthcare environment.   Stephen is joined by Joe Hendrickson, Head of Strategy and Corporate Development for Serovia, for a conversation focused on how manufacturers identify unmet market needs, evaluate product opportunities, prioritize development pathways, and make strategic decisions amid growing industry pressure.   The discussion explores how pharmaceutical companies move from early-stage ideation to portfolio evaluation, development, commercialization, and lifecycle planning. As manufacturers face rising pricing pressure, market access barriers, regulatory expectations, competitive intensity, supply chain constraints, and evolving stakeholder demands, disciplined portfolio strategy has become more important than ever.   Listeners will gain perspective on how manufacturers are navigating uncertainty, adapting their growth strategies, and building more resilient portfolio models designed to bring meaningful therapies and solutions to market. Special Guest Joe Hendrickson Head of Strategy and Corporate Development Serovia

Join us as we preview the World Cup, the only way we know how, chaos and prop bets!

Interest in macrocyclic peptides (MCPs) continues to grow, which means manufacturers are facing mounting pressure to develop production methods capable of supporting commercial-scale demand of these molecules. While they offer a unique combination of potency, selectivity, and drug-like properties, the structural complexity of MCPs has historically made them difficult and costly to manufacture using traditional peptide synthesis techniques. As a result, new manufacturing approaches are emerging that aim to improve efficiency, scalability, and sustainability while expanding access to this promising class of therapeutics. In this episode of Off Script, we spoke with David Thaisrivongs, executive director, head of biocatalysis at Merck, about research recently published in Science detailing a biocatalytic manufacturing process for enlicitide, an investigational oral macrocyclic peptide designed to lower LDL cholesterol. The conversation explores the limitations of conventional solid-phase peptide synthesis, how Merck leveraged enzyme-driven manufacturing and crystallization strategies to significantly reduce process complexity, and why minimizing chromatography can be critical for commercial-scale peptide production. He also discussed the broader implications of biocatalysis for manufacturing increasingly complex therapeutic modalities and how the technology could help shape the future of pharmaceutical production.

US President Trump said they are negotiating with Iran, and a victory will happen very soon, while he stated they will declare total victory in two weeks.US President Trump said Israel and Iran agreed to leave each other alone for another week.US equity futures continue to gain; FTSE 100 underperforms as Pharma giants fall. DXY returns below 100.00 handle, Kiwi outperforms while GBP gains following strong BRC sales. Fixed income benchmarks are tentatively firmer as geopolitical tensions ease.Crude continues to soften amid halted Iran-Israeli strikes; metals supported by softer dollar and positive risk toneLooking ahead, highlights include Mexican Inflation (May), US ADP Weekly Change, Exports/Imports, Atlanta Fed GDP, Existing Home Sales (May), Wholesale Inventories (Apr), Canadian Exports/Imports (Apr), EIA STEO (Jun), Comments from ECB President Lagarde, Supply from the US.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

In this episode, Jack Cochran sits down with Yasmeen Hyder, an enterprise solutions consulting leader from Atlanta, to explore a game-changing approach to working with AI: speaking to it instead of typing. Yasmeen shares how she uses voice-based AI interactions as a thought companion and coaching tool to enhance decision-making, reduce mental load, and work more efficiently in her presales leadership role. Follow Us Connect with Jack Cochran: https://www.linkedin.com/in/jackcochran/  Connect with Yasmeen Hyder: https://www.linkedin.com/in/yasmeenhyder/  Links and Resources Mentioned Join Presales Collective Slack: https://www.presalescollective.com/slack  Sol/Con 2026 (Chicago, August 2026): https://www.presalescollective.com/solcon-2026  Presales Collective Podcast: https://www.presalescollective.com/podcast  Key Topics Covered Voice AI vs. Typing: Why Speaking Creates Higher Bandwidth Communication AI as Thought Companion Rather Than Answer Engine Yasmeen's Career Journey: Healthcare to Pharma to Tech Presales Overcoming the Behavioral Change of Talking to Your Computer Stress Testing Leadership Decisions with Voice AI Using AI as a Coach: Asking for Questions Instead of Answers Time Compression Benefits: 60-90 Minutes Down to 15-20 Minutes Addressing Zoom Fatigue: Voice AI as Reset and Grounding Tool Negative Prompting Technique for Better Outputs Personal and Professional Applications Beyond Work Timestamps 00:00 Introduction 02:45 Welcome Yas 05:45 Why talking to AI 08:02 Setup and behavioral change 10:57 Writing vs. speaking 15:27 Rubber ducky but better 16:28 Stress testing leadership decisions 20:46 Using AI as a coach 22:36 Addressing Zoom fatigue 26:00 Personal life applications 30:19 Closing and contact information  

Regulatory volatility, scientific‑grade context requirements, and entrenched legacy processes are creating a level of operational complexity in pharma that makes even high‑value AI initiatives difficult to move from concept to production. In this episode, Art Shectman, CEO at Elephant Ventures, examines with host Marilie Fouché how leaders can cut through that complexity by isolating a single, clearly defined workflow slice and rebuilding it for near‑term, dependable deployment rather than long‑range architectural perfection. The discussion highlights how removing outdated process assumptions, selecting an atomic workflow with organizational alignment, and aiming for a contained operational win enable pharma teams to build momentum and scale AI responsibly in highly regulated environments. Learn how consultants are winning business with evidence-based AI ROI and building long-term capabilities instead of chasing short-term gains. Download our free PDF report, "3 Keys to Thriving in the Coming Era of Automation," at emerj.com/cok1

The Nurses Report with Ashley, Nicole, & David – FDA leadership shifts as Kyle Diamantas steps into power, raising alarms over his past work defending pharmaceutical companies in Abilify litigation. The story connects Mirapex, hidden safety signals, sealed settlements, and regulatory failure, arguing that drug victims face impossible burdens while pharma profits from secrecy, influence, and institutional protection today...

The Nurses Report with Ashley, Nicole, & David – FDA leadership shifts as Kyle Diamantas steps into power, raising alarms over his past work defending pharmaceutical companies in Abilify litigation. The story connects Mirapex, hidden safety signals, sealed settlements, and regulatory failure, arguing that drug victims face impossible burdens while pharma profits from secrecy, influence, and institutional protection today...

In today's episode on 4th June 2026, we talk about India's first homegrown drug and why it took Indian pharma so long to get here.Book a FREE call with Ditto

Dr. Tom Elliott has spent more than four decades at the forefront of diabetes, endocrinology, and metabolic health.He is the founder and medical director of BC Diabetes, an associate professor at UBC, and has been involved in more than 20 pharmaceutical clinical trials exploring the future of obesity, diabetes, and GLP-1 therapies. In this episode, Dr. Elliott breaks down why obesity, insulin resistance, and prediabetes have exploded across modern society, and why many founders and high performers are quietly damaging their metabolic health through stress, poor sleep, alcohol, sedentary work, and overstimulation.We explore the science behind Ozempic, GLP-1 agonists, retatrutide, testosterone decline, fertility, fasting, aging, addiction, and the future of preventative medicine. Dr. Elliott also explains why some patients in clinical trials “begged to stop” after losing too much weight, and how these drugs may extend far beyond weight loss into addiction recovery and longevity research.You will learn:Why more than 150 million Americans may be prediabeticWhat GLP-1 drugs actually do inside the bodyWhy Ozempic is affecting fertility, appetite, and addictionHow stress and sleep deprivation damage metabolismWhy muscle mass and strength matter as you ageThe relationship between testosterone, aging, and performanceHow modern food environments accelerate obesity and insulin resistanceThis is a wide-ranging conversation on diabetes, longevity, performance, and the future of human health with one of Canada's leading endocrinologists.

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Most pharma launch frameworks don't fail because they lack structure; they fail because they become rigid checklists that kill strategic thinking. In this episode, Lumanity's Business Development Director, Jeff Hart, and Launch Excellence Principal, Kirsty Tait, talk about how pharmaceutical companies can scale launch excellence as pipelines grow and complexity increases. Kirsty and Jeff explain that rigid, one-size-fits-all frameworks lead to inefficiency, slow decisions, and misalignment across global and local teams. Instead, organizations need a standardized operating system with built-in flexibility to tailor strategy by asset and market. Ultimately, success depends not just on process, but on strong governance, a single source of truth, and a winning culture that drives execution. If your launch process feels slow, inconsistent, or overly complex, this conversation will help you rethink how to scale without losing speed or impact. Resources: Follow Lumanity on LinkedIn and explore their website! Connect with and follow Kirsty Tait on LinkedIn. Connect with and follow Jeff Hart on LinkedIn. Take a look at the Launch Excellence Health Check here! Learn more about this series we're doing with Lumanity here: https://lumanity.com/commercialization-podcasts

In Part 2 of this conversation, Dr. Sina McCullough returns to unpack what may be one of the most overlooked—and unsettling—developments in our food system.   She introduces the concept of "pharma crops"—foods like corn, rice, and lettuce that are being genetically engineered to produce pharmaceutical compounds, including vaccines. While this technology has been in development for decades, Sina explains why its potential entry into the food supply raises serious questions about safety, transparency, and control.   We also explore the gaps in regulation—how these crops are tested (or not), what happens when contamination occurs, and why consumers are often left in the dark. Sina walks us through the "GRAS" loophole—"generally recognized as safe"—and how thousands of chemicals have entered our food supply without meaningful oversight.   From there, we take a closer look at what's actually in our food today… why labels like "gluten-free" can be misleading… and how processed foods dominate the modern diet.   Finally, Sina brings it back to the individual—offering a grounded and empowering perspective on how to navigate all of this without fear. She shares simple but powerful steps for becoming a more informed consumer and reconnecting with your body's own wisdom. This episode is both eye-opening and empowering—a call to look more closely at what we eat, how it's produced, and the choices we make every day. WAPF Ad- WAPF is active on IG, FB, MeWe & Telegram - Join us! Visit Dr. Sina McCullough's website to learn more Join the Nourishing Our Children closed Facebook group Check out our sponsors:  Nutrition Therapy Institute "WAPF listeners get 50% off their first course " and  Goddess Vitality From Optimal Carnivore - "Discount code WESTON10 for 10% off."

This is a corporate-focused, conversational interview between Pharmacy Podcast Network Host, Todd Eury and Stephen Beckman, CEO of YARAL Pharma. The discussion explores YARAL Pharma's unique approach to the U.S. generics market, its commitment to innovation and accessibility, and the company's philosophy of “Doing Things Differently” by redefining what it means to be a generics partner. Stephen Beckman also shares insights into YARAL's growth and key milestones since launching its first product in 2023, including the expansion of its product portfolio, investment in business development, and focus on building a strong company culture.

Stay informed on current events, visit www.NaturalNews.com  - Memorial Day Message and Introduction to Energy Technology (0:02) - Impact of the War in Iran on Energy Technology (3:59) - Commercialization and Future of LENR Technology (8:00) - Challenges and Opportunities in Energy Transition (9:11) - Memorial Day Sale and Store Updates (9:34) - Translation Projects and Future Plans (12:26) - Impact of the War in Iran on Global Energy Supply (14:56) - Advancements in Battery Technology (36:37) - Challenges in Data Center Development (56:16) - Potential for Decentralized Power Production (1:17:59) - X AI's Tactics and Community Pushback (1:18:16) - Health Impact of Gas Turbines (1:20:33) - Community Action and Activist Movements (1:22:41) - Technological Overkill and Data Center Viability (1:29:53) - China's Role in Data Center Scaling (1:33:58) - Digital ID and Surveillance Infrastructure (1:37:57) - The Spiritual and Practical Implications of Data Centers (1:46:01) - The Role of Decentralized Technology (1:53:12) - The Impact of Social Media and Addictions (2:06:28) - The Importance of Natural Dopamine Support (2:11:30) - Impact of Media and Pharma on Public Perception (2:33:51) - Awareness and Establishment Resistance (2:36:03) - Historical and Current Pharma Scandals (2:39:20) - Natural Solutions and Superfoods (2:41:33) - Impact of Toxic Ingredients and Seed Oils (2:45:28) - Glyphosate and Corporate Influence (2:53:25) - Personal Responsibility and Health Awareness (2:57:10) - Addiction Rescue Course and Dopamine Revolution (3:00:05) - Memorial Day Sale and Health Ranger Store (3:03:35) - Final Thoughts and Encouragement (3:08:55) Watch more independent videos at http://www.brighteon.com/channel/hrreport  ▶️ Support our mission by shopping at the Health Ranger Store - https://www.healthrangerstore.com ▶️ Check out exclusive deals and special offers at https://rangerdeals.com ▶️ Sign up for our newsletter to stay informed: https://www.naturalnews.com/Readerregistration.html Watch more exclusive videos here: